|
gptkbp:instance_of
|
gptkb:Fuchsia
|
|
gptkbp:advocacy
|
gptkb:European_Haemophilia_Consortium
gptkb:Hemophilia_Federation_of_America
|
|
gptkbp:associated_with
|
gptkb:von_Willebrand_disease
chronic pain
increased risk of infections
joint damage
psychosocial issues
|
|
gptkbp:breeding_range
|
Xq28
|
|
gptkbp:caused_by
|
deficiency of factor VIII
|
|
gptkbp:clinical_trial
|
gptkb:gene_therapy
new factor VIII products
|
|
gptkbp:complication
|
gastrointestinal bleeding
hemarthrosis
intracranial hemorrhage
|
|
gptkbp:condition
|
gptkb:hemophilia_B
|
|
gptkbp:diagnosis
|
blood test
family history
laboratory tests
clinical history
|
|
gptkbp:difficulty_levels
|
moderate
mild
severe
|
|
gptkbp:emergency_treatment
|
cryoprecipitate
factor VIII concentrate
fresh frozen plasma
|
|
gptkbp:first_described_by
|
1866
|
|
gptkbp:funding
|
gptkb:NIH
private foundations
|
|
gptkbp:genetic_studies
|
F8 gene mutation
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
hemophilia A
|
|
gptkbp:inherits_from
|
X-linked recessive
|
|
gptkbp:is_involved_in
|
gptkb:World_Federation_of_Hemophilia
gptkb:National_Hemophilia_Foundation
|
|
gptkbp:long_term_management
|
patient education
physical therapy
regular check-ups
|
|
gptkbp:management
|
prophylactic treatment
|
|
gptkbp:patient_population
|
primarily males
rare in females
|
|
gptkbp:prevalence
|
1 in 5,000 male births
|
|
gptkbp:public_awareness
|
gptkb:National_Hemophilia_Awareness_Month
gptkb:World_Hemophilia_Day
|
|
gptkbp:research_areas
|
biologics
gene editing
new therapies
|
|
gptkbp:risk_factor
|
family history
|
|
gptkbp:screening_test
|
activated partial thromboplastin time (a PTT)
|
|
gptkbp:symptoms
|
joint pain
easy bruising
prolonged bleeding
|
|
gptkbp:treatment
|
personalized medicine
emergency care
desmopressin
factor VIII replacement therapy
antifibrinolytics
long-acting factor VIII products
non-factor therapies
|
|
gptkbp:bfsParent
|
gptkb:von_Willebrand_disease
gptkb:Emicizumab
|
|
gptkbp:bfsLayer
|
5
|